Tweets
ICYMI:
European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
ICYMI:
European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
Oligoarticular vs. Polyarticular Psoriatic Arthritis
https://t.co/lQVNdmWgMc https://t.co/ZjyDeYTLe2
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
We've got a new podcast up for you, focusing on all of this week's top stories on RheumNow.
https://t.co/xYzkw3zGRt https://t.co/A75Cl3WYno
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
Cochrane review finds only 2 studies showing tocilizumab to be beneficial in GCA (sustained remission, relapse-free survival, need for escape therapy). https://t.co/sQjIBAiWKN
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
Swedish study of 287 SLE pts shows rare risk of autoimmune liver disease. While 14% had persistent LFTs, only 2.8% dx w/ autoimmune hepatitis. 1.4-2.1% met criteria for primary biliary cholangitis. Both AIH & PBC AIH are overrepresented in SLE https://t.co/oc5SLJtycf
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
Metanalysis of 36 studies, 608 RA-Bronchiectasis among 8569 RA pts; pooled bronchiectasis prevalence in RA was 18.7% (range 15.5% to 20.7%). Risk factors: older age, longer RA duration, genetics (CFTR & HLA), undetectable MBL biomarker https://t.co/SSRoTCYkHf
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs
https://t.co/XO4DPXwGQi https://t.co/S9E3yENfDF
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
Brazilian national study of 319 SLE & 251,800 nonSLE pts hospitalized with COVID-19 showed that SLE increases risk of death (RR 1.74) & poor outcomeS (RR 1.39). Having lupus doubled (RR 2.2) the risk of risk of death. https://t.co/8VJjdOEuzS
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
A prospective study evaluated the value and associations with morning stiffness (MS) in patients with clinically suspect arthralgia (CSA), and found that the presence of MS increases the odds of inflammation (as detected by CRP and MRI synovitis).
https://t.co/4j5Zshn48a https://t.co/2UUguqpckF
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
2021–22 influenza season coincides with continued COVID infx & Sxs may be confused betw both. ACIP Influenza vaccination guidelines: 1. Annual flu vaccine rec to all >6mos; 2. COVID Vax can be given w/ Flu Vax; 3. give before Nov 2021 https://t.co/oIkl50GI0W
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
Comparing COVID vaccines in rheum dz pts - 45 took J&J vax compared to 994 on mRNA vaccines. Detectable Ab responses lower w/ J&J (80% vs 92%, p=0.03) than mRNA vax. RTX, MMF & steroids significantly depressed Ab responses https://t.co/6ZJU8EVF5n
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 11 months ago
